May 1, 2026 · Form 4 insider transaction
Sloan Sheldon bought 78,333 shares of Spyre Therapeutics, Inc. at $27.46 per share, a transaction worth $2.15M. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 0 days after the transaction.
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.